Identification by genomic immunization of a pool of DNA vaccine candidates that confer protective immunity in mice against Neisseria meningitidis serogroup B

Vaccine

Volumn 25, Issue 28, 2007, Pages 5175-5188

  Yero, Daniel ^a,b   Pajón, Rolando ^b   Pérez, Yusleydis ^b   Fariñas, Mildrey ^a   Cobas, Karem ^b   Diaz, Daiyana ^a   Solis, Rosa L ^a   Acosta, Armando ^a   Brookes, Charlotte ^c   Taylor, Stephen ^c   Gorringe, Andrew ^c  

^a FINLAY INSTITUTE   (Cuba)

^b CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Expression library; Genomic immunization; Neisseria meningitidis

Indexed keywords

ALUMINUM DERIVATIVE; DNA VACCINE; MENINGOCOCCUS VACCINE; PLASMID VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTEREMIA; BACTERIAL STRAIN; CONTROLLED STUDY; GENOMICS; IMMUNIZATION; MALE; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS;

ANIMALS; ANIMALS, NEWBORN; BACTEREMIA; BLOTTING, WESTERN; DNA, BACTERIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENOMIC LIBRARY; IMMUNE SERA; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MICE; MICE, INBRED BALB C; MICROBIAL VIABILITY; NEISSERIA MENINGITIDIS, SEROGROUP B; PLASMIDS; RATS; SURVIVAL ANALYSIS; VACCINATION; VACCINES, DNA;

EID: 34250365388     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.04.084     Document Type: Article

References (73)

1. Rosenstein N.E., Perkins B.A., Stephens D.S., Popovic T., and Hughes J.M. Meningococcal disease. N Engl J Med 344 18 (2001) 1378-1388
2. van Deuren M., Brandtzaeg P., and van der Meer J.W. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev 13 1 (2000) 144-166 Table
3. Perrett K.P., and Pollard A.J. Towards an improved serogroup B Neisseria meningitidis vaccine. Expert Opin Biol Ther 5 12 (2005) 1611-1625
4. Peltola H., Safary A., Kayhty H., Karanko V., and Andre F.E. Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: a clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides. Pediatrics 76 1 (1985) 91-96
5. Mitka M. New vaccine should ease meningitis fears. JAMA 293 12 (2005) 1433-1434
6. Finne J., Leinonen M., and Makela P.H. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 2 8346 (1983) 355-357
7. Wyle F.A., Artenstein M.S., Brandt B.L., Tramont E.C., Kasper D.L., Altieri P.L., et al. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis 126 5 (1972) 514-521
8. Bjune G., Hoiby E.A., Gronnesby J.K., Arnesen O., Fredriksen J.H., Halstensen A., et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338 8775 (1991) 1093-1096
9. Sierra G.V., Campa H.C., Varcacel N.M., Garcia I.L., Izquierdo P.L., Sotolongo P.F., et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 14 2 (1991) 195-207
10. Tappero J.W., Lagos R., Ballesteros A.M., Plikaytis B., Williams D., Dykes J., et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 281 16 (1999) 1520-1527
11. Perkins B.A., Jonsdottir K., Briem H., Griffiths E., Plikaytis B.D., Hoiby E.A., et al. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis 177 3 (1998) 683-691
12. Claassen I., Meylis J., van der L.P., Peeter C., Brons H., Robert J., et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 14 10 (1996) 1001-1008
13. Boutriau D., Poolman J., Borrow R., Findlow J., Domingo J.D., Puig-Barbera J., et al. Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin Vaccine Immunol 14 1 (2007) 65-73
14. Comanducci M., Bambini S., Brunelli B., Adu-Bobie J., Arico B., Capecchi B., et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 195 11 (2002) 1445-1454
15. Grifantini R., Bartolini E., Muzzi A., Draghi M., Frigimelica E., Berger J., et al. Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nat Biotechnol 20 9 (2002) 914-921
16. Masignani V., Comanducci M., Giuliani M.M., Bambini S., Adu-Bobie J., Arico B., et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 197 6 (2003) 789-799
17. Tettelin H., Saunders N.J., Heidelberg J., Jeffries A.C., Nelson K.E., Eisen J.A., et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 287 5459 (2000) 1809-1815
18. Pizza M., Scarlato V., Masignani V., Giuliani M.M., Arico B., Comanducci M., et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287 5459 (2000) 1816-1820
19. Giuliani M.M., Adu-Bobie J., Comanducci M., Arico B., Savino S., Santini L., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 103 29 (2006) 10834-10839
20. Plested J.S., Harris S.L., Wright J.C., Coull P.A., Makepeace K., Gidney M.A., et al. Highly conserved Neisseria meningitidis inner-core lipopolysaccharide epitope confers protection against experimental meningococcal bacteremia. J Infect Dis 187 8 (2003) 1223-1234
21. Moe G.R., and Granoff D.M. Molecular mimetics of Neisseria meningitidis serogroup B polysaccharide. Int Rev Immunol 20 2 (2001) 201-220
22. Bruge J., Bouveret-Le Cam N., Danve B., Rougon G., and Schulz D. Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine 22 9-10 (2004) 1087-1096
23. Donnelly J.J., Liu M.A., and Ulmer J.B. Antigen presentation and DNA vaccines. Am J Respir Crit Care Med 162 4 Pt. 2 (2000) S190-S193
24. Barry M.A., and Johnston S.A. Biological features of genetic immunization. Vaccine 15 8 (1997) 788-791
25. Gurunathan S., Klinman D.M., and Seder R.A. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 18 (2000) 927-974
26. Barry M.A., Lai W.C., and Johnston S.A. Protection against mycoplasma infection using expression-library immunization. Nature 377 6550 (1995) 632-635
27. Piedrafita D., Xu D., Hunter D., Harrison R.A., and Liew F.Y. Protective immune responses induced by vaccination with an expression genomic library of Leishmania major. J Immunol 163 3 (1999) 1467-1472
28. Melby P.C., Ogden G.B., Flores H.A., Zhao W., Geldmacher C., Biediger N.M., et al. Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library. Infect Immunol 68 10 (2000) 5595-5602
29. Scorza T., Grubb K., Smooker P., Rainczuk A., Proll D., and Spithill T.W. Induction of strain-transcending immunity against Plasmodium chabaudi adami malaria with a multiepitope DNA vaccine. Infect Immunol 73 5 (2005) 2974-2985
30. Huntley J.F., Stabel J.R., Paustian M.L., Reinhardt T.A., and Bannantine J.P. Expression library immunization confers protection against Mycobacterium avium subsp. paratuberculosis infection. Infect Immunol 73 10 (2005) 6877-6884
31. Ivey F.D., Magee D.M., Woitaske M.D., Johnston S.A., and Cox R.A. Identification of a protective antigen of Coccidioides immitis by expression library immunization. Vaccine 21 27-30 (2003) 4359-4367
32. Almazan C., Kocan K.M., Bergman D.K., Garcia-Garcia J.C., Blouin E.F., and de la Fuente J. Identification of protective antigens for the control of Ixodes scapularis infestations using cDNA expression library immunization. Vaccine 21 13-14 (2003) 1492-1501
33. Stemke-Hale K., Kaltenboeck B., DeGraves F.J., Sykes K.F., Huang J., Bu C.H., et al. Screening the whole genome of a pathogen in vivo for individual protective antigens. Vaccine 23 23 (2005) 3016-3025
34. Li D., Borovkov A., Vaglenov A., Wang C., Kim T., Gao D., et al. Mouse model of respiratory Chlamydia pneumoniae infection for a genomic screen of subunit vaccine candidates. Vaccine 24 15 (2006) 2917-2927
35. Yero C.D., Pajon F.R., Caballero M.E., Cobas A.K., Lopez H.Y., Farinas M.M., et al. Immunization of mice with Neisseria meningitidis serogroup B genomic expression libraries elicits functional antibodies and reduces the level of bacteremia in an infant rat infection model. Vaccine 23 7 (2005) 932-939
36. Saukkonen K. Experimental meningococcal meningitis in the infant rat. Microb Pathog 4 3 (1988) 203-211
37. Altschul S.F., Madden T.L., Schaffer A.A., Zhang J., Zhang Z., Miller W., et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucl Acids Res 25 17 (1997) 3389-3402
38. Bendtsen J.D., Nielsen H., Von Heijne G., and Brunak S. Improved prediction of signal peptides: signalP 3.0. J Mol Biol 340 4 (2004) 783-795
39. Pajon R., Yero D., Lage A., Llanes A., and Borroto C.J. Computational identification of beta-barrel outer-membrane proteins in Mycobacterium tuberculosis predicted proteomes as putative vaccine candidates. Tuberculosis (Edinb) 86 3-4 (2006) 290-302
40. Marchler-Bauer A., Anderson J.B., Cherukuri P.F., DeWeese-Scott C., Geer L.Y., Gwadz M., et al. CDD: a conserved domain database for protein classification. Nucl Acids Res 33 (2005) D192-D196 Database issue
41. Thompson J.D., Higgins D.G., and Gibson T.J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucl Acids Res 22 22 (1994) 4673-4680
42. Fredriksen J.H., Rosenqvist E., Wedege E., Bryn K., Bjune G., Froholm L.O., et al. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann 14 2 (1991) 67-79
43. Maslanka S.E., Gheesling L.L., Libutti D.E., Donaldson K.B., Harakeh H.S., Dykes J.K., et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol 4 2 (1997) 156-167
44. Holbein B.E. Iron-controlled infection with Neisseria meningitidis in mice. Infect Immunol 29 3 (1980) 886-891
45. Findlow J., Taylor S., Aase A., Horton R., Heyderman R., Southern J., et al. Comparison and correlation of Neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac. Infect Immunol 74 8 (2006) 4557-4565
46. Scarselli M., Giuliani M.M., Adu-Bobie J., Pizza M., and Rappuoli R. The impact of genomics on vaccine design. Trends Biotechnol 23 2 (2005) 84-91
47. Rappuoli R., and Covacci A. Reverse vaccinology and genomics. Science 302 5645 (2003) 602
48. Dietrich G. DNA microarrays in vaccine research. Curr Opin Mol Ther 5 6 (2003) 575-583
49. Barry M.A., Howell D.P., Andersson H.A., Chen J.L., and Singh R.A. Expression library immunization to discover and improve vaccine antigens. Immunol Rev 199 (2004) 68-83
50. Talaat A.M., and Stemke-Hale K. Expression library immunization: a road map for discovery of vaccines against infectious diseases. Infect Immunol 73 11 (2005) 7089-7098
51. Goldschneider I., Gotschlich E.C., and Artenstein M.S. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 129 6 (1969) 1307-1326
52. Welsch J.A., and Granoff D. Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity. Infect Immunol 72 10 (2004) 5903-5909
53. West D., Reddin K., Matheson M., Heath R., Funnell S., Hudson M., et al. Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection. Infect Immunol 69 3 (2001) 1561-1567
54. Welsch J.A., Moe G.R., Rossi R., Adu-Bobie J., Rappuoli R., and Granoff D.M. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis 188 11 (2003) 1730-1740
55. Gorringe A.R., Reddin K.M., Funnell S.G., Johansson L., Rytkonen A., and Jonsson A.B. Experimental disease models for the assessment of meningococcal vaccines. Vaccine 23 17-18 (2005) 2214-2217
56. Toropainen M., Kayhty H., Saarinen L., Rosenqvist, Hoiby E.A., Wedege E., et al. The infant rat model adapted to evaluate human sera for protective immunity to group B meningococci. Vaccine 17 20-21 (1999) 2677-2689
57. Sun Y., Li Y., Exley R.M., Winterbotham M., Ison C., Smith H., et al. Identification of novel antigens that protect against systemic meningococcal infection. Vaccine 23 32 (2005) 4136-4141
58. Welsch J.A., Rossi R., Comanducci M., and Granoff D.M. Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J Immunol 172 9 (2004) 5606-5615
59. O'dwyer C.A., Reddin K., Martin D., Taylor S.C., Gorringe A.R., Hudson M.J., et al. Expression of heterologous antigens in commensal Neisseria spp.: preservation of conformational epitopes with vaccine potential. Infect Immunol 72 11 (2004) 6511-6518
60. Olin P., Rasmussen F., Gustafsson L., Hallander H.O., and Heijbel H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Lancet 350 9091 (1997) 1569-1577
61. Lissolo L., Maitre-Wilmotte G., Dumas P., Mignon M., Danve B., and Quentin-Millet M.J. Evaluation of transferrin-binding protein 2 within the transferrin-binding protein complex as a potential antigen for future meningococcal vaccines. Infect Immunol 63 3 (1995) 884-890
62. Madico G., Welsch J.A., Lewis L.A., McNaughton A., Perlman D.H., Costello C.E., et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 177 1 (2006) 501-510
63. Rosenqvist E., Hoiby E.A., Wedege E., Bryn K., Kolberg J., Klem A., et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immunol 63 12 (1995) 4642-4652
64. Gioia C.A., de Sousa A.B., Cruz S.C., Junior F.C., Andrade A.F., Sassi R.M., et al. Effect of a booster dose of serogroup B meningococcal vaccine on antibody response to Neisseria meningitidis in mice vaccinated with different immunization schedules. FEMS Immunol Med Microbiol 44 1 (2005) 35-42
65. Pollard A.J., Galassini R., Rouppe van der Voort E.M., Hibberd M., Booy R., Langford P., et al. Cellular immune responses to Neisseria meningitidis in children. Infect Immunol 67 5 (1999) 2452-2463
66. Uli L., Castellanos-Serra L., Betancourt L., Dominguez F., Barbera R., Sotolongo F., et al. Outer membrane vesicles of the VA-MENGOC-BC(R) vaccine against serogroup B of Neisseria meningitidis: analysis of protein components by two-dimensional gel electrophoresis and mass spectrometry. Proteomics 6 11 (2006) 3389-3399
67. van Den Elsen J.M., Herron J.N., Hoogerhout P., Poolman J.T., Boel E., Logtenberg T., et al. Bactericidal antibody recognition of a PorA epitope of Neisseria meningitidis: crystal structure of a Fab fragment in complex with a fluorescein-conjugated peptide. Proteins 29 1 (1997) 113-125
68. Delvig A.A., Wedege E., Michaelsen T.E., Hoiby E.A., Brandtzaeg P., and Rosenqvist E. Immune responses to linear epitopes on the PorB protein of Neisseria meningitidis in patients with systemic meningococcal disease. Microbiology 142 Pt. 9 (1996) 2491-2498
69. Giuliani M.M., Santini L., Brunelli B., Biolchi A., Arico B., DiMarcello F., et al. The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infect Immunol 73 2 (2005) 1151-1160
70. Granoff D.M., Moe G.R., Giuliani M.M., Adu-Bobie J., Santini L., Brunelli B., et al. A novel mimetic antigen eliciting protective antibody to Neisseria meningitidis. J Immunol 167 11 (2001) 6487-6496
71. Laddy D.J., and Weiner D.B. From plasmids to protection: a review of DNA vaccines against infectious diseases. Int Rev Immunol 25 3-4 (2006) 99-123
72. Liu M.A., and Ulmer J.B. Human clinical trials of plasmid DNA vaccines. Adv Genet 55 (2005) 25-40
73. Krieg A.M., Yi A.K., Schorr J., and Davis H.L. The role of CpG dinucleotides in DNA vaccines. Trends Microbiol 6 1 (1998) 23-27